-$0.30 EPS Expected for Intec Pharma (NTEC) This Quarter
Brokerages forecast that Intec Pharma (NASDAQ:NTEC) will report earnings per share (EPS) of ($0.30) for the current quarter, Zacks reports. Zero analysts have issued estimates for Intec Pharma’s earnings, with the lowest EPS estimate coming in at ($0.32) and the highest estimate coming in at ($0.25). Intec Pharma posted earnings per share of ($0.40) in the same quarter last year, which indicates a positive year over year growth rate of 25%. The company is expected to issue its next quarterly earnings results on Wednesday, November 21st.
According to Zacks, analysts expect that Intec Pharma will report full year earnings of ($1.28) per share for the current financial year, with EPS estimates ranging from ($1.43) to ($0.93). For the next fiscal year, analysts forecast that the company will post earnings of ($0.96) per share, with EPS estimates ranging from ($1.05) to ($0.68). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Intec Pharma.
Several research firms have recently weighed in on NTEC. HC Wainwright set a $16.00 price objective on Intec Pharma and gave the company a “buy” rating in a research report on Thursday, August 16th. Oppenheimer set a $15.00 price objective on Intec Pharma and gave the stock a “buy” rating in a research note on Wednesday, August 15th. Zacks Investment Research upgraded Intec Pharma from a “hold” rating to a “buy” rating and set a $5.50 price objective for the company in a research note on Tuesday, May 15th. Roth Capital restated a “buy” rating and issued a $10.00 target price on shares of Intec Pharma in a research note on Tuesday, June 26th. Finally, ValuEngine upgraded Intec Pharma from a “sell” rating to a “hold” rating in a research note on Tuesday, May 8th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. Intec Pharma currently has a consensus rating of “Buy” and a consensus target price of $12.25.
Several large investors have recently added to or reduced their stakes in NTEC. Renaissance Technologies LLC lifted its position in shares of Intec Pharma by 66.0% during the 4th quarter. Renaissance Technologies LLC now owns 133,500 shares of the biotechnology company’s stock valued at $688,000 after acquiring an additional 53,100 shares during the period. Deutsche Bank AG increased its stake in shares of Intec Pharma by 59.2% in the fourth quarter. Deutsche Bank AG now owns 115,217 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 42,867 shares during the period. Millennium Management LLC acquired a new stake in shares of Intec Pharma in the fourth quarter valued at about $1,392,000. JPMorgan Chase & Co. bought a new stake in shares of Intec Pharma during the 1st quarter valued at about $138,000. Finally, ETF Managers Group LLC bought a new stake in shares of Intec Pharma during the 1st quarter valued at about $175,000. Hedge funds and other institutional investors own 35.76% of the company’s stock.
Intec Pharma Company Profile
Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.
Read More: Short Selling Stocks, A Beginner’s Guide
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.